Revista nº 802

182 David Fernández Garay Abordaje de la trombosis en cáncer 8. Jara L, Solier A, Elias T, et al . Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study. Thrombosis Research. 2017; 157: 90-96. 9. Raskob GE, van Es N, Verhamme O, et al . Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2017. 10. Carrier M, Le Gal G, Cho R, Tierney S, Rodger M, Lee AY. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost. 2009; 7:760-5. 11. Ihaddadene R, Le Gal G, Delluc A, Carrier M. Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis. Thromb Res. 2014; 134:93-5. 12. Louzada ML, Carrier M, Lazo-Langner A, et al . Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer associated venous thromboembolism. Circulation 2012; 126: 448–54. 13. den Exter PL, Kooiman J, Huisman MV. Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis. J Thromb Haemost 2013; 11: 998–1000. 14. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low molecular weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002; 162: 1729-35. 15. Lee AY, Levine MN, Baker RI, et al. Low molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146–53.